Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03617484
Title Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Michigan Cancer Center

mantle cell lymphoma


Bortezomib + Ibrutinib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.